SAB Biotherapeutics (SABS) EBT (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly EBT came in at -$46.5 million in Q1 2026, down 323.92% YoY from $20.8 million in Q1 2025, and down 207.34% on a QoQ basis from -$15.1 million in Q4 2025.
SAB Biotherapeutics (SABS) EBT (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of EBT data on file, last reported at -$46.5 million in Q1 2026.
- Quarterly EBT fell 323.92% year-over-year to -$46.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.8 million (down 121.91% YoY) and the FY2025 annual result came in at -$73.6 million, down 71.9% from the prior year.
- EBT slipped to -$46.5 million in Q1 2026, from -$15.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $1.1 million in Q1 2022 to a low of -$46.5 million in Q1 2026.
- A 5-year average of -$11.1 million and a median of -$7.8 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT sank 782.08% — and 2024, when it jumped 58.11%.
- Tracing SABS's EBT over 5 years: stood at -$7.8 million in 2022, then slumped by 191.21% to -$22.9 million in 2023, then jumped by 58.11% to -$9.6 million in 2024, then sank by 58.04% to -$15.1 million in 2025, then plunged by 207.34% to -$46.5 million in 2026.
- The last three EBT figures came in at -$46.5 million (Q1 2026), -$15.1 million (Q4 2025), and -$12.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | -50.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.77 Mn |
| Mar 31, 2026 | -46.51 Mn |
| Dec 31, 2025 | -15.13 Mn |
| Sep 30, 2025 | -12.75 Mn |
| Jun 30, 2025 | -10.45 Mn |
| Mar 31, 2025 | -10.97 Mn |
| Dec 31, 2024 | -9.57 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.87 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |